Komori
Kaken Pharmaceutical (4521) · InitiativeAdvanced

Preparations for New Accounting Standards

First written in FY2018. 10 of 15 entries say "Restated". Latest entry: FY2026.

15entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019-Q2 – FY2021RestatedFY2022-Q2 – FY2023-Q3AdvancedFY2025-H1 – FY20262018: 320182019: 220192020: 020202021: 320212022: 420222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Preparation for the Adoption of Multiple New Accounting StandardsA theme 140 companies write about · 3 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2025: 7 of 74 companies on the "Worse" side.

51 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 140 companies compared. The sentences above are computed from all 140.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「"Accounting Standard for Leases" (ASBJ Statement No. 34, 13 September 2024). It is scheduled to be applied from the beginning of the fiscal year ending March 2028.」

    Regarding the new lease accounting standard, the company disclosed plans to apply it from the beginning of the fiscal year ending March 2028 and has begun assessing the impact.
  2. FY2025-H1AdvancedAnnual report

    「We have applied the Accounting Standard for Income Taxes, Inhabitant Taxes and Enterprise Taxes (ASBJ Statement No. 27, October 28, 2022, hereinafter the “2022 Revised Accounting Standard”) and other standards from the beginning of the interim consolidated accounting period.」

    The 2022 amendments to the accounting standards and related implementation guidance were applied from the beginning of the interim consolidated accounting period. There is reportedly no impact on the interim consolidated financial statements.
  3. FY2023-Q3RestatedAnnual report

    「The company applied the Implementation Guidance on Accounting Standard for Fair Value Measurement (ASBJ Guidance No. 31, 17 June 2021, hereinafter the "Fair Value Measurement Guidance") from the beginning of the first quarter of the fiscal year. In accordance with the transitional treatment prescribed in paragraph 27-2 of the Fair Value Measurement Guidance, the new accounting policies prescribed in the Fair Value Measurement Guidance will be applied prospectively. There is no impact on the quarterly consolidated financial statements.」

    The company reconfirms that it applied the Fair Value Measurement Guidance from the beginning of the first quarter of the fiscal year and that there is no impact on the quarterly consolidated financial statements.
  4. FY2023-Q2RestatedAnnual report

    「The company applied the Implementation Guidance on Accounting Standard for Fair Value Measurement (ASBJ Guidance No. 31, 17 June 2021, hereinafter the "Fair Value Measurement Guidance") from the beginning of the first quarter of the fiscal year. In accordance with the transitional treatment prescribed in paragraph 27-2 of the Fair Value Measurement Guidance, the new accounting policies prescribed in the Fair Value Measurement Guidance will be applied prospectively. There is no impact on the quarterly consolidated financial statements.」

    The company reconfirms that it applied the Fair Value Measurement Guidance from the beginning of the first quarter of the fiscal year and that there is no impact on the quarterly consolidated financial statements.
  5. FY2023-Q1RestatedAnnual report

    「The Guidance on Accounting Standard for Fair Value Measurement (Accounting Standards Implementation Guidance No. 31, 17 June 2021; hereinafter, the “Fair Value Measurement Guidance”) was applied from the beginning of the first quarter of the current consolidated fiscal year. In accordance with the transitional treatment prescribed in paragraph 27-2 of the Fair Value Measurement Guidance, the new accounting policies prescribed by the guidance will be applied prospectively. There was no impact on the quarterly consolidated financial statements.」

    The company states that it applied the Implementation Guidance on Accounting Standard for Fair Value Measurement from the beginning of the first quarter. This reconfirms the adoption of the new accounting standard disclosed in the first quarter of the previous fiscal year, with no impact on the financial statements.
  6. FY2022RestatedAnnual report

    「In the consolidated statements of income, net sales decreased by ¥1,154 million and cost of sales decreased by ¥1,142 million, while the impact on operating profit, ordinary profit and profit before income taxes was immaterial.」

    Regarding the revenue recognition accounting standard applied from the beginning of the fiscal year ending March 2022, the cumulative annual impact on net sales and cost of sales was disclosed. The impact on operating profit and other items remains immaterial.
  7. FY2022-Q3RestatedAnnual report

    「As a result, net sales and cost of sales for the first nine months of the current fiscal year decreased by ¥783 million and ¥846 million, respectively, but the impact on operating profit, ordinary profit and profit before income taxes was immaterial.」

    Regarding the revenue recognition accounting standard applied from the beginning of the first quarter of the fiscal year, the cumulative third-quarter impact was a ¥783 million decrease in net sales and a ¥846 million decrease in cost of sales. The impact on operating profit and other items remains immaterial.
  8. FY2022-Q2RestatedAnnual report

    「As a result, net sales and cost of sales for the first six months of the current fiscal year decreased by ¥560 million and ¥588 million, respectively, but the impact on operating profit, ordinary profit and profit before income taxes was immaterial.」

    Details were provided on the revenue recognition standard applied from the beginning of the first quarter of the current fiscal year, including the recognition of licence revenue, contract up-front payments and milestone revenue, as well as the presentation of transactions involving agents on a net basis. The impact was also shown as a ¥560 million decrease in net sales and a ¥588 million decrease in cost of sales.
  9. FY2022-Q1AchievedAnnual report

    「The company applied the Accounting Standard for Revenue Recognition (Accounting Standards Board of Japan Statement No. 29, 31 March 2020) and related standards from the beginning of the first quarter of the current fiscal year, and began recognizing revenue at the amount expected to be received in exchange for the promised goods or services when control of those goods or services transfers to the customer.」

    The revenue recognition standard, which had been scheduled for application from the beginning of the fiscal year ending March 2022 through the previous fiscal year, was applied from the beginning of the first quarter of the current fiscal year. The accounting standard for fair value measurement and other standards were also applied from the same date. Application of the revenue recognition standard reduced net sales by ¥314 million, while the impact on operating profit and other measures was considered immaterial.
  10. FY2021RestatedAnnual report

    「The standard is scheduled to be applied from the beginning of the fiscal year ending March 2022.」

    In addition to the revenue recognition standard, the accounting standard for fair value measurement and other standards were scheduled to be applied from the beginning of the fiscal year ending March 2022, with the amounts of all impacts still under assessment.
  11. FY2019RestatedAnnual report

    「The standard is scheduled to be applied from the beginning of the fiscal year ending March 2022.」

    The revenue recognition standard was scheduled to be applied from the beginning of the fiscal year ending March 2022, with the amount of the impact continuing to be assessed. The amended standards related to tax-effect accounting were applied from the beginning of the current fiscal year.
  12. FY2019-Q3RestatedAnnual report

    「The Partial Amendments to Accounting Standard for Tax Effect Accounting (Accounting Standards Board of Japan Statement No. 28, 16 February 2018) and other standards have been applied from the beginning of the first quarter of the consolidated fiscal year. Deferred tax assets are presented under investments and other assets, while deferred tax liabilities are presented under non-current liabilities.」

    The application of the amended standards related to tax-effect accounting from the beginning of the first quarter of the current fiscal year was reconfirmed in the third quarter.
  13. FY2019-Q2RestatedAnnual report

    「The Partial Amendments to Accounting Standard for Tax Effect Accounting (Accounting Standards Board of Japan Statement No. 28, 16 February 2018) and other standards have been applied from the beginning of the first quarter of the consolidated fiscal year. Deferred tax assets are presented under investments and other assets, while deferred tax liabilities are presented under non-current liabilities.」

    The application of the amended standards related to tax-effect accounting from the beginning of the first quarter of the current fiscal year was reconfirmed in the second quarter.
  14. FY2019-Q1AdvancedAnnual report

    「The partial amendments to the Accounting Standard for Tax Effect Accounting and related standards have been applied from the beginning of the first quarter of the consolidated fiscal year. Deferred tax assets are presented under investments and other assets, and deferred tax liabilities under non-current liabilities.」

    The amended standards related to tax-effect accounting, which had been scheduled for application in the previous year, were actually applied from the beginning of the first quarter of the current fiscal year.
  15. FY2018First statedAnnual report

    「“Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, 30 March 2018) and “Implementation Guidance on Accounting Standard for Revenue Recognition” (ASBJ Guidance No. 30, 30 March 2018)」

    The revenue recognition standard was scheduled to be applied from the beginning of the fiscal year ending March 2022, and the five-step revenue recognition process was described. The application guidelines and other guidance related to tax-effect accounting were also scheduled to be applied from the fiscal year ending March 2019, with the amount of the impact still under assessment.
Moved together

"Continuation of R&D investment" moved the same way as this thread, in the same document, in 4 of its 15 moves.

4422★1234
  1. ★This thread
  2. 1Continuation of R&D investment4×
  3. 2Implementation of Shareholder Returns4×
  4. 3Pharmaceutical licensing in Japan and overseas2×
  5. 4Decline in Real Estate Business Revenue and Profit2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.